| Business Summary | | Neurogen
Corporation
is
a
drug
discovery
company
that
applies
its
proprietary
discovery
platform
to
discover
and
commercialize
new
drugs
for
a
broad
range
of
pharmaceutical
uses.
The
Company
is
focused
on
discovering
new
small
molecule
drugs
(i.e.
drugs
that
can
be
taken
as
a
pill)
for
large
market
disorders
where
existing
therapies
achieve
limited
therapeutic
effects
or
produce
unsatisfactory
side
effects.
In
multiple
programs,
the
Company
has
applied
its
AIDD
(Accelerated
Intelligent
Drug
Discovery)
platform
to
discover
drug
candidates
that
work
through
well
validated
biological
targets
in
the
body,
but
for
which
the
pharmaceutical
industry
has
had
limited
or
no
success
in
discovering
viable
drug
candidates. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Neurogen
Corp.
is
a
pharmaceutical
company
engaged
in
the
discovery
and
development
of
a
new
generation
of
drugs
which
are
designed
to
selectively
regulate
the
communication
between
cells
in
order
to
influence
cell
function.
For
the
six
months
ended
6/30/01,
revenues
fell
28%
to
$5.2
million.
Net
loss
before
acct.
change
rose
1%
to
$13.6
million.
Results
reflect
reduced
amounts
earned
from
Pfizer,
partially
offset
by
lower
stock
compensation
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Frank Carlucci, 70 Chairman | -- | -- | Harry Penner, Jr., 55 Vice
Chairman, Pres, CEO | $1.9M | $3.3M | Stephen Davis, 40 Sr.
VP and CBO | 1.1M | 673K | Alan Hutchison, Ph.D., 47 Sr.
VP-Drug Discovery | 1.2M | 385K | Kenneth Shaw, Ph.D., 44 Sr.
VP - Chemistry and Pre-Clinical Devel. | 999K | 350K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|